Risk of SARS-CoV-2 infection and subsequent hospital admission and death at different time intervals since first dose of COVID-19 vaccine administration, Italy, 27 December 2020 to mid-April 2021-Reference-Cited by-同舟云学术

Risk of SARS-CoV-2 infection and subsequent hospital admission and death at different time intervals since first dose of COVID-19 vaccine administration, Italy, 27 December 2020 to mid-April 2021

Published:2021-06-24 Issue:25 Volume:26 Page:
ISSN:1560-7917
Container-title:Eurosurveillance
language:en
Short-container-title:

Author:

Mateo-Urdiales Alberto¹²^ORCID,Spila Alegiani Stefania³,Fabiani Massimo²,Pezzotti Patrizio²,Filia Antonietta²,Massari Marco³,Riccardo Flavia²,Tallon Marco⁴,Proietti Valeria⁵,Del Manso Martina¹²,Puopolo Maria⁶,Spuri Matteo²,Morciano Cristina⁷,D’Ancona Fortunato (Paolo)²,Da Cas Roberto³,Battilomo Serena⁵,Bella Antonino²,Menniti-Ippolito Francesca³, ,

Affiliation:

1. European Programme for Intervention Epidemiology Training (EPIET), European Centre for Disease Prevention and Control (ECDC), Stockholm, Sweden

2. Department of Infectious Diseases, Istituto Superiore di Sanità, Rome, Italy

3. National Centre for Drug Research and Evaluation, Istituto Superiore di Sanità, Rome, Italy

4. Department of Informatics, Istituto Superiore di Sanità, Rome, Italy

5. DG-SISS, Ministero della Salute, Rome, Italy

6. Department of Neuroscience, Istituto Superiore di Sanità, Rome, Italy

7. Research Coordination and Support Service, Istituto Superiore di Sanità, Rome, Italy

Abstract

To assess the real-world impact of vaccines on COVID-19 related outcomes, we analysed data from over 7 million recipients of at least one COVID-19 vaccine dose in Italy. Taking 0–14 days post-first dose as reference, the SARS-CoV-2 infection risk subsequently decreased, reaching a reduction by 78% (incidence rate ratios (IRR): 0.22; 95% CI: 0.21–0.24) 43–49 days post-first dose. Similarly, hospitalisation and death risks decreased, with 89% (IRR: 0.11; 95% CI: 0.09–0.15) and 93% (IRR: 0.07; 95% CI: 0.04–0.11) reductions 36–42 days post-first dose. Our results support ongoing vaccination campaigns.

Publisher

European Centre for Disease Control and Prevention (ECDC)

Subject

Virology,Public Health, Environmental and Occupational Health,Epidemiology

Reference13 articles.

1. Agenzia Italiana del Farmaco (AIFA). Vaccini COVID-19. Rome: AIFA. [COVID-19 Vaccines]. [Accessed 19 May 2021]. Available from: https://www.aifa.gov.it/vaccini-covid-19

2. Ministero della Salute. Piano strategico per la vaccinazione anti-SARS-CoV-2/COVID-19. [Strategic plan for SARS-CoV-2 / COVID-19 vaccination]. Rome: Ministero della Salute; 2020. Italian. Available from: https://www.trovanorme.salute.gov.it/norme/renderNormsanPdf?anno=2021&codLeg=78657&parte=1&serie=null

3. Epidemiological characteristics of COVID-19 cases and estimates of the reproductive numbers 1 month into the epidemic, Italy, 28 January to 31 March 2020.;Riccardo;Euro Surveill,2020

4. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine.;Polack;N Engl J Med,2020

5. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine.;Baden;N Engl J Med,2021

Cited by 27 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effectiveness against severe COVID-19 of a seasonal booster dose of bivalent (original/Omicron BA.4-5) mRNA vaccines in persons aged ≥60 years: Estimates over calendar time and by time since administration during prevalent circulation of different Omicron subvariants, Italy, 2022–2023;Vaccine;2024-10

2. Impact of non-pharmaceutical interventions on COVID-19 incidence and deaths: cross-national natural experiment in 32 European countries;BMC Public Health;2024-08-28

3. Risk of breakthrough infection and hospitalisation after COVID-19 primary vaccination by HIV status in four Italian regions during 2021;BMC Public Health;2024-06-11

4. The impact of underreported infections on vaccine effectiveness estimates derived from retrospective cohort studies;International Journal of Epidemiology;2024-04-11

5. Risk Factors for Long COVID in Older Adults;Biomedicines;2023-11-08